VanEck Biotech ETF (BBH) Valuation
BBH valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 82.0 trailing earnings
- Forward P/E
- 19.0 analyst estimates
- Price / sales
- 6.50
- Price / book
- 6.33
- EV / EBITDA
- 16.9
- Earnings yield
- 1.22% inverse of P/E
- Dividend yield
- 0.70% of the holdings
- Return on equity
- 7.7% combined
- Net margin
- 7.9% combined
- Beta
- 0.68 weighted, vs S&P 500
BBH valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| BBH | 82.0 | 19.0 | 6.50 | 6.33 | 0.70% | 7.7% | 7.9% | 37.1% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
BBH valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 99.5% | 82.0 | 19.0 | 6.50 | 6.33 | 0.70% | 7.7% |
BBH earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How BBH weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
BBH largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 15.55% | 26.9 | 16.7 | 6.1 | 2.33% | 47.73% |
| GILD | Gilead Sciences, Inc. | 13.66% | — | 15.6 | 6.4 | 2.10% | −19.11% |
| VRTX | Vertex Pharmaceuticals Incorporated | 8.40% | 28.9 | 24.1 | 10.1 | — | 23.94% |
| REGN | Regeneron Pharmaceuticals, Inc. | 7.02% | 19.6 | 14.5 | 5.2 | 0.48% | 29.59% |
| MRNA | Moderna, Inc. | 6.49% | — | 23.0 | 39.1 | — | −19.58% |
| NTRA | Natera, Inc. | 4.70% | — | — | 20.9 | — | −1.33% |
| IQV | IQVIA Holdings Inc. | 4.54% | 33.2 | 18.4 | 2.6 | — | 11.28% |
| ARGX | argenx SE | 4.22% | 31.2 | 25.9 | 9.7 | — | 11.13% |
| ILMN | Illumina, Inc. | 4.08% | 49.0 | 40.3 | 8.8 | — | 6.86% |
| RVMD | Revolution Medicines, Inc. | 3.75% | — | — | 9,035.1 | — | −15.39% |
| BIIB | Biogen Inc. | 3.08% | 41.3 | 13.9 | 3.4 | — | 6.15% |
| ONC | BeiGene, Ltd. | 2.82% | 66.0 | 35.2 | 6.9 | — | 3.53% |
| GH | Guardant Health, Inc. | 2.74% | — | — | 18.0 | — | −4.98% |
| UTHR | United Therapeutics Corporation | 2.36% | 19.1 | 16.4 | 7.2 | — | 10.18% |
| ALNY | Alnylam Pharmaceuticals, Inc. | 2.33% | 39.1 | 19.7 | 6.5 | — | 4.91% |
| INCY | Incyte Corporation | 2.16% | 14.4 | 14.7 | 3.9 | — | 12.38% |
| INSM | Insmed Incorporated | 1.67% | — | 97.1 | 18.5 | — | −5.85% |
| CRL | Charles River Laboratories International, Inc. | 1.66% | — | 22.4 | 3.6 | — | −2.19% |
| NBIX | Neurocrine Biosciences, Inc. | 1.44% | 19.9 | 14.1 | 4.1 | — | 5.97% |
| BNTX | BioNTech SE | 1.35% | — | 7.0 | 8.3 | — | −9.90% |
| ICLR | ICON Public Limited Company | 1.34% | 179.1 | 14.7 | 1.6 | — | 0.62% |
| TECH | Bio-Techne Corporation | 1.15% | 62.6 | 34.6 | 9.4 | 0.44% | 1.52% |
| QGEN | Qiagen N.V. | 1.04% | 23.4 | 13.5 | 4.5 | 0.76% | 3.67% |
| BMRN | BioMarin Pharmaceutical Inc. | 0.99% | 147.8 | 9.4 | 3.1 | — | 0.55% |
| TEM | Tempus AI, Inc. | 0.93% | — | — | 8.2 | — | −1.66% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About BBH valuation
Adding up its 25 holdings with company data, BBH trades at 82.0 times trailing earnings and 19.0 times analysts' forward estimates, with a price-to-book ratio of 6.33 and a dividend yield of 0.70%. Its earnings yield of 1.22% is 4.11 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 72.4% of the fund and earn 75.1% of its combined profit. Companies that lost money over the past year are 37.1% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 100.0% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: BBH chart, BBH performance, BBH holdings, BBH dividends.
BBH valuation FAQ
What is the P/E ratio of BBH?
Based on its holdings, BBH has a trailing P/E of 82.0 and a forward P/E of 19.0 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of BBH?
The trailing earnings yield is 1.22% (1 ÷ P/E) and the forward earnings yield 5.26%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is BBH more expensive than the S&P 500?
BBH trades at 82.0 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 19.0 and 19.9.
What is the price-to-book ratio of BBH?
The holdings of BBH trade at 6.33 times book value, with a combined return on equity of 7.7%.